Ultimately, we strive to provide advanced in vitro diagnostic capabilities for analyzing cell-material interactions and drug discovery as well as innovative bioreactor solutions for the future of regenerative medicine.  Initial intellectual property was derived from the academic research efforts of the two co-founders, Orr and Gevaert, while working in conjunction with Dr. Karen Burg, Hunter Endowed Chair and Professor of Bioengineering at Clemson University.

KIYATEC lab-based technology provides more accurate simulation of phenomenon inherent within the living systems of the body.  Accurate modeling of these dynamic conditions provides opportunity for advanced medical treatments and enhanced diagnostics that will benefit society through the resulting improvements in healthcare and its associated costs.